Category: Health and wellness

Don”t miss out on business opportunities in Latin America Pharmaceutical Excipients Market

Growth in this market is driven by the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; increasing focus of MNCs on investing in the pharmaceutical and healthcare sectors in Latin America; growing pricing pressures; rapid growth in aging population & the subsequent increase in the prevalence of related diseases; and the availability of local and government funding for R&D activities. 

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41302221

Browse in-depth TOC on ‘Latin America Pharmaceutical Excipients Market

28 – Tables
11 – Figures   
281 – Pages  

By functionality, the filler & diluents segment accounted for the largest share of the Latin America Pharmaceutical Excipients Market

The Latin America Pharmaceutical Excipients Market, by functionality, is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disintegrants, lubricants & glidants, preservatives, emulsifiers & solubilizers, and other functionalities. The fillers & diluents segment accounted for the largest market share in 2018. The increased use of fillers & diluents in the development and production of solid dosage form and the wide applications of diluents in the wet granulation and direct compression process for tablet formulation are driving the growth of the fillers & diluents segment.

Request Sample Pages: 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=41302221

Mexico to dominate the Latin America Pharmaceutical Excipients Market during the forecast period

In 2018, Mexico dominated the Latin America Pharmaceutical Excipients Market, followed by Argentina. Over the past few years, Mexico has become an attractive destination for investment in the pharmaceutical industry due to its large pharmaceutical production and consumption capacity and the improved regulatory framework. Growing pharmaceutical production and consumption, increasing investments by MNCs, and improved regulatory framework are the major factors driving the growth of the pharmaceutical excipients market in Mexico.

Prominent players in the Latin America Pharmaceutical Excipients Market are DowDuPont (US), Roquette (France), Ashland (US), BASF (Germany), and Kerry Group (Ireland).

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=41302221

Browse Adjacent Markets @ Pharmaceuticals Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/latin-america-pharmaceutical-excipient-market.asp

Visit Our Website: https://www.marketsandmarkets.com

https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

CHICAGO, March 12, 2019 /PRNewswire/ — According to the new market research report Latin America Pharmaceutical Excipients Market by Functionality (Fillers, Coating, Disintegrants, Binders, Lubricants, Preservatives, Emulsifying Agents, Lubricants, Glidants, Diluents), Country (Mexico, Argentina, Columbia, Peru) – Forecast to 2024′, published by MarketsandMarkets™, the Latin America Pharmaceutical Excipients Market is projected to reach USD 579 million by 2024 from USD 403 million in 2019, at a CAGR of 7.5%.

[[[tasteofexc

Read Full Article

VALLEY COTTAGE, New York, Feb. 21, 2019 /PRNewswire/ — Sales of smart pill boxes and bottles are likely to reach around 800 thousand in 2019. According to a new analytical research study by Future Market Insights (FMI), smart pill boxes and bottles market will remain a high growth-low volume landscape over the course of next few years. Over 43% of total sales will be accounted by smart pill boxes. The report envisages a higher rate of adoption for smart pill bottles.

Almost 70% of adult patients are observed to discontinue or manipulate drug therapy, resulting in non-adherence to prescribed medication. The study opines that this directly adds to the economic burden on healthcare delivery system in form of emergency cases and hospitalization.

Smart pill boxes and bottles are increasingly being perceived as a potential solution to such challenges posed by increased healthcare delivery costs. Significance of medication adherence continues to rise with increasing prevalence of chronic conditions, propelling demand for smart pill boxes and bottles.

Request a Sample Report with Table of Contents and Figureshttps://www.futuremarketinsights.com/reports/sample/rep-gb-1710

Dementia and geriatric care remain the key application areas of smart pill boxes and bottles, according to the report. More than 80% of sales is accounted by aging patients and dementia-afflicted population. Cancer management is likely to emerge lucrative in terms of applicability in coming years.

With surging demand for high-quality healthcare delivery, senior care centers, hospitals, long-term care centers, and homecare settings are accelerating adoption of medication dispensers, thereby elevating the revenue growth of smart pill boxes and bottles market. Some of the leading companies are actively involved in the development of advanced technology medication dispensing devices with zero error risks during medication.

Buy this report @ https://www.futuremarketinsights.com/checkout/1710

Home care settings maintain the highest consumption share in smart pill boxes and bottles market that roughly equates 65% of total sales. Almost a fifth of smart pill boxes and bottles sold are installed at seniors care and assisted living centers. FMI”s analysis indicates that long-term care centers are also creating promising market opportunities for smart pill boxes and bottles manufacturers and distributors.

North America continues to reign supreme owing to early adoption of advanced technology enabled smart pill boxes and bottles, accounting for more than a third of the global market revenue. European market for smart pill boxes and bottles also represents a substantial volume share, majorly driven by German patients. South and East Asian regions are briskly developing high-potential markets for manufacturers and distributors of smart pill boxes and bottles, says the report.

Preview Analysis of Smart Pill Boxes & Bottles Market is segmented by (Type – Smart Pill Box & Smart Pill Bottles; Indication – dementia, Parkinson”s disease, cancer management, diabetes care, geriatric care, disability & others; Distribution channel – seniors care & assisted living, long term care centers & home care;) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028: https://www.futuremarketinsights.com/reports/smart-pill-boxes-bottles-market

The vendor landscape of smart pill boxes and bottles market remains fairly consolidated and competitive, as Tier 1 manufacturers continue to account for a majority of share in the market in terms of volume. While dominance of Koninklijke Philips N.V., PharmRight Corporation & Livi, and AdhereTech prevails in smart pill boxes and bottles market, the report finds that the competition among these players is characterized by product innovation, new launches, and technological advancements.

FMI has tracked market performance for a decade-old projection period – 2018-2028. For exclusive insights on the various other aspects of smart pill boxes and bottles market landscape, write to the analyst at press@futuremarketinsights.com

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with youhttps://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1710

More from Healthcare, Pharmaceuticals and Medical devices Market Insights Market Intelligence:

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Browse More Healthcare, Pharmaceuticals and Medical devices Market Insights

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44(0)20-7692-8790
Sales: sales@futuremarketinsights.com 
Press Office: Press@futuremarketinsights.com 
Blog: Market Research Blog 
Website: https:www.futuremarketinsights.com

Over 6 in 10 Smart Pill Boxes & Bottles Sell in Home Care Settings, Dementia & Geriatric Care Spur Demand Growth

[[[tasteofexc

Read Full Article

The North America market would dominate the Global Second Generation Pens Market by Region in by 2024, growing at a CAGR of 9.7 % during the forecast period. The Europe market is expected to witness a CAGR of 10.2% during (2018 – 2024). Additionally, The Asia Pacific market is expected to witness a CAGR of 11.9% during (2018 – 2024). Asia Pacific would be the fastest growing market, which offers lucrative opportunities for the market growth, due to its substantial population base and growing diabetic patients. On the other hand, affordability of the Insulin pens also propels the market growth in the region.

The Hospitals & Clinics market dominated the Global Smart Insulin Pen Market by End User in 2017. The Ambulatory Surgical Centers market is expected to witness a CAGR of 10.6% during (2018 – 2024). The major factors that drive the growth of the market include growing diabetic population, lower cost of insulin pumps, and painless injections.

Access Full Report: https://www.kbvresearch.com/smart-insulin-pen-market/

The Prefilled market dominated the Global Smart Insulin Pen Market by Usability in 2017, and would achieve a market value of $64,759.4 Thousand by 2024. The Reusable market is expected to witness a CAGR of 10.7% during (2018 – 2024).

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Companion Medical Inc., Digital Medics Ptd Ltd., Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co., Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Emperra GmbH E-Health Technologies, Jiangsu Delfu medical device Co. Ltd., Bigfoot Biomedical.

Global Smart Insulin Pen Market Segmentation

By Product 

  • Second Generation Pens
    o   USB Connected Smart Insulin Pen
    o   Bluetooth-Enabled Smart Insulin Pen
  • First Generation Pens

By Usability

  • Prefilled
  • Reusable

By End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home care settings

 By Geography

  • North America
    o   US
    o   Canada
    o   Mexico
    o   Rest of North America 
  • Europe
    o   Germany
    o   UK
    o   France
    o   Russia
    o   Spain
    o   Italy
    o   Rest of Europe 
  • Asia Pacific
    o   China
    o   Japan
    o   India
    o   South Korea
    o   Singapore
    o   Malaysia
    o   Rest of Asia Pacific 
  • LAMEA
    o   Brazil
    o   Argentina
    o   UAE
    o   Saudi Arabia
    o   South Africa
    o   Nigeria
    o   Rest of LAMEA

Companies Profiled

  • Companion Medical Inc.
  • Digital Medics Ptd Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Diamesco Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Insulet Corporation
  • Emperra GmbH E-Health Technologies
  • Jiangsu Delfu medical device Co. Ltd.
  • Bigfoot Biomedical

Unique Offerings from KBV Research

  • Exhaustive coverage  
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

About Us:

Knowledge Based Value Research is a global brand and consulting firm serving all kinds of business verticals, government and non-governmental organizations, and not-for-profit organizations. Our motto is to extend our services that will have a lasting impact on our clients who trust us with their business goals.

Our aim is to transform and customize our services to address the fast changing business needs of our clients. With innovative methods, we seek to empower our research tools with new capabilities that would eventually bring about customer delight, as we understand that businesses evolve.

Media Contact:

Mr. Alan D”Souza
KBV Research
244 Fifth Avenue, Suite 1407
New York, N.Y. 10001
United States (U.S)
Tel: +1 (646) 661-6066
Email: query@kbvresearch.com

 

NEW DELHI, Feb. 21, 2019 /PRNewswire/ — According to a new report Global Smart Insulin Pen Market, published by KBV research, The Global Smart Insulin Pen Market size is expected to reach $117.3 Million by 2024, rising at a market growth of 10.2% CAGR during the forecast period. The demand is due to rapidly rising number of diabetic patients, and cost-effectiveness of the smart insulin pens. In addition, the simple functioning and accurate delivery of appropriate dosing adds to the demand.

[[[tasteofexc

Read Full Article

FinancialBuzz.com News Commentary

Europe and the LATAM region are attractive regions for many companies to establish operations. Europe”s overall cannabis market is projected to reach USD 66.8 Billion within the next five years, while the LATAM region is expected to reach USD 12.7 Billion in sales by 2028, according to Prohibition Partners. The research notes that several European countries have passed medical marijuana legislation recently, and there is a 50% chance a few more could pass recreational laws. Meanwhile, the LATAM region is being targeted mainly for cultivation facilities due to its fertile lands and inexpensive costs associated with growing, as more countries view legalization with zest. ‘As more markets open, international trade begins and research and science take a front seat in the coming years,’ said John Billings, head of cultivation for The Farm Dispensary. ‘There”s no reason to think this trend will not continue. Growing plants/varietals with higher concentrate returns will help keep production costs down. You have old players (Israel, Jamaica, GW Pharmaceuticals and the U.S.) and new players (Canada and Mexico) coming into the scene with their own ideas and plans.’

Blueberries Medical Corp. (OTC: BBRRF) (CSE: BBM) earlier last week the company announced that it, ‘has entered into a letter of intent (the ‘Letter Agreement’) dated February 13, 2019 for a joint venture (the ‘Joint Venture’) with Harmony and Life S.A.S., operating as El Manantial medical centers (‘El Manantial‘).

The Joint Venture will further the development and commercialization of Blueberries” medicinal cannabis products through El Manantial”s rapidly growing patient base and collaboration with El Manantial”s team of physicians, pharmacists and technicians with deep expertise in a variety of medical areas. It will also provide a direct distribution channel to an established and rapidly growing patient by selling exclusively Blueberries” cannabis-derived products. The Company has also set out to build two BPE (Good Elaboration Practices) certified pharmacies in support of the initiative which will provide additional sales channels for Blueberries” products. Blueberries and El Manantial will also develop a treatment-focused medical education program designed to assist physicians in prescribing cannabis-based treatment plans to patients.

‘Our joint venture with El Manantial provides an outstanding opportunity for Blueberries to develop medical products and acquire patients in the Colombian market’, stated Christian Toro, Chief Executive Officer of the Company. ‘El Manantial is a respected leader in Colombia, and their focus on equitable access to medicine and patient care aligns with our goal of providing treatment to a broad spectrum of patients. The Joint Venture emphasizes communication with prescribing doctors and education of both doctors and patients which is expected to ensure that Blueberries is developing treatments that the medical community needs, and that a streamlined process is developed for the company to reach its patients.’

El Manantial is among the fastest growing networks of medical centers in Colombia, currently representing over 7,000 patients and expected to grow to over 50,000 patients over the next 36-month period as four new centers are projected to come online. This is an important development in Blueberries” strategy to acquire patients and develop treatments with cannabis products, positioning Blueberries as a leader in the Colombian medicinal cannabis product market.

‘This transaction will allow us the opportunity to work with the Blueberries team to develop new cannabis products and treatments, which can in turn be rolled out to our medical center network, offering patients the best possible care’, stated Dr. Andres Vidal, founder of El Manantial. ‘We plan for our prescribing physician education program to be an important step in supporting the widespread adoption of cannabis treatments in Colombia and globally.’ Dr. Vidal, who has control and direction over El Manantial, is also a director of Blueberries.

Pharmacy Build-Out: Blueberries will make a strategic investment of up to C$400,000 in the construction of specialized pharmacies that are BPE (Good Elaboration Practices) certified. In addition to the pharmacies owned and operated by El Manantrial, the Company-owned pharmacies will also sell cannabis and cannabis-derived products exclusively from Blueberries. Completion of the build-out of the Company”s pharmacies is expected to occur during Q3 2019.

Letter Agreement Terms: Collaborate on the research, development, and commercialization of Blueberries cannabis derived medicinal products.

Blueberries to be exclusive supplier of cannabis and cannabis-derived products to El Manantial for research and sale through their medical center network and pharmacies.

Blueberries will make a strategic investment of up to C$300,000 for the development of educational programs for the medical community to deliver to patients. The program will include certification for physicians obtained through comprehensive training, and it is expected to come online in Q2 2019.

Blueberries will invest up to C$100,000 for medical center facility upgrades to expand capacity in order to accommodate the rapidly growing patient base.

The proposed Joint Venture is subject to completion of satisfactory due diligence by each of the Company and El Manatial, and the execution of a definitive agreement.

About El Manantial: Founded in 2013 by Dr. Andres Vidal, El Manantial offers its patients the best of conventional medicine, and the best of alternative and complementary medicine, guaranteeing the best possible patient care. A diverse team of physicians and technicians of various specialties of conventional medicine, family medicine, nutrition, aesthetic medicine, homeopathic medicine, and natural medicine, bacteriologists, paramedics, pharmacists make El Manantial a leading center of medical expertise in Colombia. As one of the fastest growing medical center network in Colombia, the goal of El Manantial is to generate equitable access for all Colombians to medical treatment. The centers are actively engaged in the research and development of new and cutting-edge treatments to meet the needs of patients. For further information about El Manantial, please visit https://centromedicoelmanantial.co/.

About Blueberries Medical Corp: Blueberries is a Colombia-based licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá savannah of central Colombia. Led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries has received all licenses required for the cultivation, production, domestic distribution, and international export of CBD (cannabidiol) and THC (tetrahydrocannabinol)-based medical cannabis. Blueberries” combination of leading scientific expertise, agricultural advantages, and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.’

Innovative Industrial Properties, Inc. (NYSE: IIPR) is focused on the regulated U.S. cannabis industry.  Earlier this month the company announced that it closed on the acquisition of a property in Sacramento, California, which comprises approximately 43,000 square feet of industrial space. This acquisition marks IIP”s first investment in California and expands its portfolio to ten U.S. states. The purchase price for the Sacramento property was approximately $6.7 million (excluding transaction costs). Concurrent with the closing of the purchase, IIP entered into a long-term, triple-net lease agreement with an experienced operator, which intends to operate the property as a licensed cannabis cultivation facility in accordance with California regulations. The seller of the property is expected to complete redevelopment of the building, for which IIP has agreed to provide reimbursement of up to $4.8 million. Assuming full reimbursement for the redevelopment, IIP”s total investment in the property will be approximately $11.5 million.

Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids currently serving tens of thousands of patients in twelve countries spanning five continents. Tilray, Inc. recently announced that after completing an acquisition of its existing import and distribution partner Alef Biotechnology SpA, the company has officially relaunched as Tilray Latin America SpA, a wholly-owned subsidiary of Tilray. Tilray Latin America will further strengthen Tilray”s position as a global leader in the medical cannabis market. Tilray currently has medical cannabis products available in twelve countries and operates globally through its wholly-owned subsidiaries in Australia & New Zealand, Canada, Germany, and Portugal. Tilray Latin America will import, produce and distribute Tilray branded medical cannabis products in Chile and create a hub to distribute Tilray products throughout Latin America, subject to local laws. Tilray previously announced a partnership with Alef Biotechnology in February 2017 to import and distribute Tilray products in Chile and Brazil. Alef, now Tilray Latin America, is currently licensed by the Chilean government to commercially produce medical cannabis and is planning a state-of-the-art facility to domestically produce and process medical cannabis products. Chilean law permits patients to access medical cannabis products under the supervision of a recommending physician.

Village Farms International, Inc. (OTCQX: VFFIF) (TSX: VFF) is one of the largest and longest-operating vertically integrated greenhouse growers in North America and the only publicly traded greenhouse produce company in Canada. Village Farms International, Inc. recently announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. has entered into a credit agreement with Bank of Montreal (‘BMO’), as agent and lead lender and Farm Credit Canada as lender in respect of a CAD 20 Million secured non-revolving term loan. Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million sq. ft. greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes. ‘The ability to establish this Credit Facility with Bank of Montreal, a Canadian Schedule I bank, and Farm Credit Canada, the country”s leading agriculture lender, is a testament to the strength and potential of Pure Sunfarms,’ said Michael DeGiglio, Chief Executive Officer, Village Farms International. ‘Village Farms has long-standing relationships with both BMO and FCC, each of which, based on our extensive histories, recognizes and values our three decades of large-scale greenhouse production experience and deep expertise throughout the supply chain. We are pleased to now extend these relationships to Pure Sunfarms as it rapidly approaches full production at one of the single largest cannabis facilities in the world and begins to generate positive cash flow from operations as expected in the first quarter of 2019.’

iAnthus Capital Holdings, Inc. (OTCQX: ITHUF) (CSE: IAN) owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. iAnthus Capital Holdings, Inc. recently announced that it has opened its first and flagship dispensary in New York on December 30, 2018. The dispensary, located at 202 Flatbush Avenue directly across from Barclays Center and Atlantic Terminal, is the first in Brooklyn, New York”s largest borough, with a population of roughly 2.6 million people. The dispensary will operate under iAnthus” ‘Citiva’ New York dispensary brand. ‘The opening of our Brooklyn dispensary is a major milestone for iAnthus and Citiva. With an ideal location and an expert team in place, we expect this dispensary to be a major asset to the community and the Company,’ said Hadley Ford, Chief Executive Officer of iAnthus. ‘We are incredibly proud to be the first to open a dispensary in Brooklyn, which serves as a testament to iAnthus” track record of innovation and industry firsts.’

PharmaCielo Ltd. (OTC: PHCEF) (TSX-V: PCLO)  is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo Ltd., the Canadian parent of Colombia”s premier cultivator and producer of medicinal-grade cannabis oil PharmaCielo Colombia Holdings S.A.S., recently announced that it has received a 500-year-old ancestral cannabis strain for its exclusive use from the Arhuaco indigenous people. The Company received the Seeds as part of a traditional ceremony at the site of its nursery and propagation centre in Rionegro, Antioquia. The Seeds will be cultivated by PharmaCielo in the Arhuaco”s ancestral territory of the Sierra Nevada mountains. ‘Our team is grateful to the Arhuaco for their friendship and the trust they have placed in PharmaCielo to carry a strain of great cultural importance to the wider population of Colombia and other global markets,’ said Anthony Wile, Co-Founder and Chief Executive Officer of PharmaCielo Colombia’One of our primary objectives as a corporate leader in Colombia is to bring opportunity to historically exploited indigenous communities through the quality production of strains that have been in community use for hundreds of years. With a combination of pharmaceutical-grade cultivation and production standards, vastly scalable, low-cost production capacity and access to unique strains like that provided by the Arhuaco, PharmaCielo is positioned to be a global leader in the production and sale of medicinal-grade cannabis.’

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ”Site”) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For blueberries medical corp., financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

For further information:

info@financialbuzz.com 
+1-877-601-1879
Url: www.FinancialBuzz.com

NEW YORK, Feb. 19, 2019 /PRNewswire/ — The expansion of the cannabis industry has led companies involved in the marketplace to expand internationally as larger players are extending their operations into other regions such as Europe and Latin America. Cannabis is enjoying a global perspective shift on legalization, however, the industry is still heavily hindered by certain regulations. Nonetheless, many countries are exploring opportunities within the market for medical applications. Despite its continued global expansion, the U.S. continues to dominate the cannabis marketplace. According to Verified Market Intelligence, the global marijuana market was valued at USD 42.20 Billion in 2017 and is expected to reach USD 466.81 Billion by 2025. Additionally, the market is projected to register a CAGR of 35.3% throughout the forecast period from 2018 to 2025. The market is primarily being accelerated by the growing adoption of medical cannabis for the treatment of chronic diseases. However, as more U.S. states begin to legalize recreational cannabis, projections show that recreational sales could overtake medical sales in the near future. Blueberries Medical Corp. (OTC: BBRRF) (CSE: BBM), Innovative Industrial Properties, Inc. (NYSE: IIPR), Tilray, Inc. (NASDAQ: TLRY), Village Farms International, Inc. (OTC: VFFIF) (TSX: VFF), iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN).

[[[tasteofexc

Read Full Article

Don”t miss out on business opportunities in Near Infrared Imaging Market

The growth of this market is primarily driven by the increasing number of surgical procedures globally and the advantages of NIR imaging over conventional visualization methods.

Devices segment to account for the largest share of the market in 2018

Based on product, the market is segmented into devices and reagents. In 2018, the devices segment is expected to account for a larger share of the Near Infrared Imaging Market. The rising number of surgical procedures performed due to the increasing prevalence of cancer, cardiovascular diseases, neurovascular diseases, and gastrointestinal diseases is the major factor driving the demand for near infrared imaging devices.

Browse in-depth TOC on ‘Near Infrared Imaging Market

129 – Tables

36 – Figures  

175 – Pages  

Get 10% Free Customization on this Report: 

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=174869738

Cancer surgeries segment to grow at the highest CAGR during the forecast period

Based on application, the Near Infrared Imaging Market is segmented into cancer surgeries, plastic/reconstructive surgeries, gastrointestinal surgeries, cardiovascular surgeries, preclinical imaging, and other applications. The cancer surgeries segment is expected to grow at the highest CAGR during the forecast period owing to the significant growth in the prevalence of cancer across the globe.

North America to dominate the Near Infrared Imaging Market in 2018

In 2018, North America is expected to be the largest regional market for near infrared imaging. This can primarily be attributed to the high healthcare spending, rising geriatric population, increasing prevalence of target diseases, rising number of cosmetic surgeries, and the rapid adoption of technologically advanced imaging systems in the region.

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=174869738

The key players operating in the Near Infrared Imaging Market are Stryker (US), KARL STORZ SE & Co. KG (Germany), Carl Zeiss Meditec AG (Germany), Leica Microsystems (Germany), Olympus (Japan), Fluoptics (France), Hamamatsu Photonics K.K (Japan), Quest Medical Imaging B.V. (Netherlands), Mizuho Medical Co, Ltd. (Japan), Shimadzu Corporation (Japan), Visionsense (Israel), PerkinElmer, Inc. (US), LI-COR, Inc. (US), and SurgVision (Netherlands).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/near infrared-imaging-market.asp 
Visit Our Website: https://www.marketsandmarkets.com

CHICAGO, Feb. 15, 2019 /PRNewswire/ — According to the new market research report Near Infrared Imaging Market by Product Type (NIR Fluorescence Imaging, Reagents), Application (Cancer surgery, Plastic surgery, Gastrointestinal surgery) End Users (Hospitals & Clinics, Research laboratory, Pharmaceutical companies) – Global Forecast to 2023′, published by MarketsandMarkets™, the Near Infrared Imaging Market is projected to reach USD 822 million by 2023 from an estimated USD 416 million in 2018, at a CAGR of 14.6% during the forecast period of 2018 to 2023.

[[[tasteofexc

Read Full Article

According to the new market research report Ligation Devices Market by Product (Hand-held Instruments, Accessories), Procedure (Minimally Invasive & Open Surgery), Application (Gynaecology, GIT, Cardiothoracic, Urology), End User (Hospital, Nursing Homes) – Global Forecast to 2024′, published by MarketsandMarkets™, the Ligation Devices Market is expected to reach USD 1,189 million by 2024 from USD 876 million in 2019, at a CAGR of 6.3%.

Don”t miss out on business opportunities in Ligation Devices Market

Accessories dominated the Ligation Devices Market in 2018

By product, the Ligation Devices Market is segmented into handheld instruments and accessories. In 2018, the accessories segment accounted for the largest share of the market. The large share of this product segment can be attributed to the increasing volume of surgical procedures resulting in high demand for accessories.

Browse in-depth TOC on ‘Ligation Devices Market

80 – Tables

30 – Figures  

110 – Pages  

Get 10% Free Customization on this Report: 

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=22007372

Gastrointestinal & abdominal surgeries held the largest share of the applications market in 2018

Based on applications, the Ligation Devices Market is segmented into gastrointestinal & abdominal surgeries, gynecological surgeries, cardiovascular surgeries, urological surgeries, and other applications such as wound, ENT, and cosmetic applications. In 2018, the gastrointestinal & abdominal surgeries segment accounted for the largest share of the Ligation Devices Market. The large share of this segment can be attributed to the increasing incidence of gastrointestinal cancer and the growing number of cholecystectomy and hernia treatment procedures.

Hospitals were the largest end users of ligation devices in 2018

By end user, the Ligation Devices Market is segmented into hospitals and other end users. The hospitals segment accounted for the largest market share in 2018 while the other end users segment is projected to grow at the highest CAGR during the forecast period. The large volume of surgical procedures performed in hospitals is the major factor driving the growth of this segment.

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=22007372

North America commanded the largest share of the Ligation Devices Market in 2018

North America commanded the largest share of the Ligation Devices Market. The large share of North America in this market can be attributed to the increasing prevalence of cancer and hernia, the growing number of bariatric surgeries, growing healthcare expenditure, increasing preference for MIS, and the favorable reimbursement scenario for laparoscopic surgeries.

Some of the major players in this market include Ethicon (Johnson and Johnson) (US), Teleflex Incorporated (US), Olympus (Japan), Applied Medical (US), ConMed (US), Cooper Surgical (US), Genicon (US), Grena Think Medical (UK), B.Braun (Germany), and Medtronic (Ireland).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/ligation-device-market.asp 
Visit Our Website: https://www.marketsandmarkets.com

 

CHICAGO, Feb. 11, 2019 /PRNewswire/ —

[[[tasteofexc

Read Full Article

Push Doctor, the UK”s leading digital health provider, has selected Datix as its patient safety software provider, moving patient safety beyond the physical walls of the healthcare provider and into the burgeoning virtual healthcare space. Push Doctor will deploy three Datix modules – Incident, Dashboard, and Risk Register – which will enable the digital physician practice to transform its current reporting system by improving accuracy of incident reports, standardising reports, and triangulating incident and risk data to identify improvement opportunities.

Push Doctor provides digital consultations to hundreds of thousands of patients each year. Push Doctor selected Datix not only for its established expertise and credibility, but also for the patient safety best practices Datix has developed from more than 30 years of working with healthcare providers to reduce preventable patient harm.

‘A key differentiator was that the Datix system could be configured around our individual policies, processes, and culture,’ said Wais Shaifta, CEO of Push Doctor. ‘The connectivity between incident and risk data is key to us, as it will provide us with a complete overview of all of our data and allow us to more accurately pinpoint areas for improvement, something that we couldn”t do with our previous system. We”re keen to start standardising our processes and improving accuracy with Datix.’

Push Doctor”s GPs are located remotely throughout the UK, which has posed a challenge in creating a clear or easy process for reporting incidents or risks. With Datix, however, all users will now have access to an instant incident reporting function, which will improve reporting rates, accuracy, and – ultimately – safety.

The three modules being implemented will provide Push Doctor with a user-friendly system that will make for easy engagement and standardisation of best practices for the diverse background that make up the online service. Employing a strong incident management tool will mean users can focus on their specialities and automate event notification. In addition, reports will be simplified, making them easier to understand, and stored in a central repository, eliminating challenges Push Doctor has previously experienced with management reporting.

‘Datix is on the leading edge of revolutionising healthcare”s approach to patient safety, and Push Doctor is on the leading edge of transforming the healthcare delivery system – which is why we are so excited about this partnership,’ said Claire Aldred, Datix Vice President Commercial UK and EU. ‘Two innovative companies working together to enhance the fast-growing online healthcare sector will create learning opportunities that this new alliance will open up for the benefit of patients across the UK.’

About Datix 
Datix has been a global pioneer in the field of patient safety over the past three decades and today is the leading provider of software for patient safety, risk management and incident reporting for the healthcare sector.

Datix aims to build and promote a culture of safety within healthcare organisations, recruiting professionals who are passionate about improving healthcare and championing technological innovation. Datix continually invests in its software and services, maintaining a leadership position at the forefront of the worldwide patient safety movement.

Datix is focused on the health and social care sector. Its customers include public and private hospitals, primary care providers, GP surgeries, mental health and ambulance service providers. Within the UK this includes over 80% of the National Health Service. Internationally the Datix client base is growing rapidly and includes large scale deployments in the USA and Canada as well as customers in Europe, Australia and the Middle East. Datix has offices in London, Chicago and Washington DC, with partners in the Middle East, Australia and New Zealand.

About Push Doctor 
Push Doctor was the UK”s first platform to offer video consultations with patients online and via smartphone – offering quick, easy and convenient access to NHS trained doctors.

Today, Push Doctor connects thousands of patients each week with a UK GP, with appointments available in just minutes.

The service treated over 1,000 different condition types last year including a wide range of infections, gastric, respiratory and mental health conditions. 9 out of 10 people got the help they needed first time.

The brand continues to evolve to encompass a broader range of medical conditions, health, wellness and lifestyle products / services as it treats the nation, with the core goal of enabling its customers to live happier, longer lives.

LONDON, January 29, 2019 /PRNewswire/ —

[[[tasteofexc

Read Full Article

U.S. food supplement ingredients market revenue to witness growth at over 7% to 2024 as growing occurrence of various chronic disease such as diabetes, heart attacks and arthritis will boost requirements for dietary supplements owing to their ample health benefits driving industry growth.

     (Logo: https://mma.prnewswire.com/media/661916/GMI.jpg )

Food Supplement Ingredient Market size will exceed USD 2 Billion by 2024, according to new forecast statistics by Global Market Insights, Inc. Increasing obesity rates among children and adults owing to change in lifestyle patterns and consumption of food products may drive the food supplement ingredients market demand. Increasing trend towards weight management among working professional group owing to hectic lifestyle may drive the product demand.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/3097

Food supplement ingredients requirement is rapidly growing owing to their rich nutrient content, of vitamins, iron, and minerals which are further required for balanced nutrition. Companies are highly engaged in marketing their food supplement products to athletes thereby increasing their sports performance. Well-trained and recreational athletes require these food and dietary supplements for improving performance and achieve a viable edge.

Vitamin B12 food supplement ingredient was valued at over USD 60 million in 2017. These are served as a supplement ingredient which can be taken in the form of tablets or powder. Significant vitamin B12 deficiency among geriatric population is creating a huge health concern where food supplements play a vital role in the production of DNA, nerves, and blood cells which is likely to stimulate market growth.

Food supplement ingredients from amino acid may register significant growth at over 4.5% by the end of forecast period. Amino acids are used by various gym professionals as they aid in muscle building and are considered essential in burning fats. These supplements also aid in improving sports performance for athletes, which may drive the product demand.

Browse key industry insights spread across 250 pages with 312 market data tables and 32 figures & charts from the report, Food Supplement Ingredients Market Size, By Product (Vitamins {Vitamin A, Vitamin C, Vitamin B6, Vitamin B12, Vitamin D}, Amino Acid, Probiotics, Omega-3, Collagen Peptides, Folic Acid, Oxalic Acid, Magnesium, Iron), By Form (Powder, Liquid, Tablets, Capsules, Gel), By End-Use (Infant, Children, Adults, Pregnant Women, Old-Aged), Industry Analysis Report, Regional Outlook (U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Poland, China, India, Japan, South Korea, Indonesia, Malaysia, Thailand, Brazil, South Africa, Saudi Arabia, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 2024 in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/food-supplement-ingredients-market

Food supplement ingredients in capsule form was valued at over USD 155 million in 2017. Easy availability & absence of odour in capsules along with an upsurge in chronic diseases among the significant elderly population should promote the food supplement market growth of products in capsule forms.

Food supplement ingredients from pregnant women was valued at over USD 105 Million in 2017. Growing cases of delayed childbirths owing to a rise in the number of working women, disposable incomes, and growing prescription of prenatal vitamin supplements to improve embryo health should stimulate the product demand. Furthermore, these products offer various nutrients such as iron, folic acid, calcium, and iodine, which minimize the risk of neural tube defects at birth and fill dietary gaps in pregnant women, which should boost market growth.

Germany food supplement market from vitamin is anticipated to surpass USD 100 million by 2024. Growing adoption of these products owing to their consumption for maintaining overall health may drive the regional demand. Increasing trend towards self-medication owing to increasing awareness regarding OTC products may drive the regional industry growth.

Make an Inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/3097

China food supplement ingredients from amino acid was valued at over 5 million in 2017. Sports is an essential part in Chinese culture which require various nutritional products to boost their overall performance. Amino acid aid in building muscle and reduce fat levels in the body maintain a balanced weight, which may drive the regional growth.

Naturex, Nestle, Lonza, Herbalife Nutrition and Pfizer are key players in food supplement ingredients market. Introduction of new products and continuous enhancement in R&D may drive the industry growth.

Browse More New Reports: 

1. Oryzanol Market Size By Application (Pharmaceuticals, Cosmetics, Nutraceuticals & Sport Supplements), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Russia, China, India, Japan, South Korea, Thailand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Global Oryzanol Market size was worth over USD 1.4 billion in 2018 and will witness over 13% CAGR up to 2025.

Read more @ https://www.gminsights.com/industry-analysis/oryzanol-market

2. Isoflavones Market Size By Source [Soy (Food & Beverages, Nutraceuticals, Cosmetics), Chickpea (Food & Beverages, Nutraceuticals, Cosmetics), Red Clover (Food & Beverages, Nutraceuticals, Cosmetics)] Industry Analysis Report, Regional Outlook (U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Poland, Denmark, China, India, Japan, South Korea, Thailand, Australia, Malaysia, Brazil, Argentina, Saudi Arabia, UAE, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025.

Global Isoflavones Market size was over USD 13.5 billion in 2018 and industry expects consumption above 650 kilo tons by 2025.

Read more @ https://www.gminsights.com/industry-analysis/isoflavones-market

About Global Market Insights 

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

 

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: +1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com  

Web: https://www.gminsights.com 
Latest News: http://cmferesearch.com/category/food-and-beverages/

SELBYVILLE, Delaware, January 29, 2019 /PRNewswire/ —

[[[tasteofexc[[[tasteofexc

Read Full Article

FN Media Group Presents Safehaven.com News Commentary

Wayland Group (WAYL.CN – MRRCF) can produce cannabis at $0.05 a gram in South American and sells cannabis for up to $16 in some European markets. How do they do it? With a simple, but powerful business strategy. Mentioned in today”s commentary includes: Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group (NASDAQ: CRON) (TSX: CRON), Aurora Cannabis (NYSE: ACB) (TSX: ACB), Emblem Corp. (OTC: EMMBF) (TSX.V: EMC), THC Biomed International (OTC: THCBF) (CSE: THC).

Wayland focuses on the lowest cost production methods. Produce product in countries with weaker currencies. Sell into the highest-paying markets that have strong currencies. And don”t think because they focus on lowering the cost of production that this is a lower grade product.

Because the Wayland Group (WAYL.CN ; MRRCF) just hit one of the greatest benchmarks a cannabis producer can hit. They”ve achieved GMP Certification (Good Manufacturing Practice). The only other 4 Canadian cannabis producers who hit this milestone are industry giants now.

If you know cannabis investing, then you know these names:

  • Aurora Cannabis Inc now about $5.64 a share
  • Cronos Group Inc now about $11.35 a share
  • Canopy Growth Corporation now about $29.61 a share
  • Tilray, Inc now about $74 a share

Wayland has joined them as one of only 5 Canadian producers who are GMP certified producers for the European Union. It”s impressive because Wayland”s a much smaller company.

Why does the ability to sell into the European Union matter? Two reasons: First, because medical cannabis in Europe commands some of the highest prices per gram in the world. The insurance coverage in Europe for medical use of cannabis is widespread. Second, because of the currency exchange. Canadian producers are bearing production costs in Canadian dollars but selling in Euros. (One euro is worth roughly $1.52 Canadian.)

That is part of the reason why, in Canada, Wayland sells cannabis at an average $5.56 per gram. But in Europe Wayland (WAYL.CN; MRRCF) can sell it for up to $16 Canadian dollars per gram. That”s three times the price.

Wayland has taken this idea of low-cost production and high buying markets to an extreme their investors love

They automated production to reduce their workforce from 500 people down to just 26. And payroll costs can add enormous amounts to a company”s overhead (and eat away at margins).

For instance, the minimum wage in Canada is $14 per hour. And paying 500 people at $14 per hour for a 40-hour work week means you”re paying $280,000 per week in payroll. Over 52 weeks that balloons to over $14 million in payroll costs. But not at Wayland. By reducing staff to just 25 employees at a production facility through automation they”ve dramatically reduced costs.

The 4 cost-cutting secrets to these gross margins

  1. Technology is on their side

Wayland uses an AI Master Grower so they only need a fraction of the workforce of many labor intensive operations.

This cannabis producer has a world-class tech team. By using artificial intelligence and big data they have automated cannabis production to an astounding degree. Some of their competitors need up to 500 employees to match the production of Wayland”s staff of 26. That”s 5% of some competitors” workforce.

  2. Smart strategic alliances

The AI Master Grower is powered by Rockwell Automation, and Wayland is the first cannabis company to embrace automation as a key feature of the cultivation process. With a tiny staff, Wayland can produce thousands of grams of cannabis for export.
That brings production costs way, way down. At the Langton facility in Canada, Wayland deploys the AI Master Grower to oversee 365,000 square feet and a potential annual capacity of 95,000 kilos.

  3. They cut energy costs to a fraction

When cannabis was illegal, one way police would look for growers was to find places with massive energy costs. That”s because traditional production methods require enormous amounts of energy. Those costs cut into profits.
Wayland went through every step and cost of production to find ways to cut costs. The company can cut big costs by embracing renewable energy sources and energy efficient practices. Their facilities are powered by natural gas co-generation and they utilize recycled water for their hydroponics, which cuts down on waste that can accumulate from bad growth practices. The company has worked out a quick-dry method with former JPL scientists.

  4. VESIsorb Tech means customers need to take less to get the same effect

Wayland has also brought advances in pharmaceuticals to cannabis cultivation. The company has deployed VESIsorb medical tech for its cannabis products.
When cannabinoids are ingested, they enter the body but tend to get clumped in the digestive system, interfering with absorption and diminishing the overall effect. VESIsorb disperses the CBD molecules so they”re easier to absorb, providing higher and more immediate levels of CBD absorption. The company”s automated production techniques, energy efficiency and global reach means it can get its product to the market at a cost lower than many competitors all around the world.

In 2019, cannabis will enter the mainstream. Demand is set to grow. And Wayland”s low production costs will give it an edge over its competitors.

Savvy investors need pay attention.

Other companies transforming the cannabis sector:

Aurora Cannabis (NYSE:ACB) (TSX:ACB)

Recently, Aurora sealed a supply deal with Mexico”s Farmacias Magistrales SA, the country”s first and, for now, at least, only federally licensed importer of raw materials containing THC.

In an announcement from Aurora, the company stated that the deal ‘firmly establishes Aurora”s first-mover advantage in one of the world”s most populous countries, where more than 130 million people will have federally legal access to a range of Aurora”s non-flower medical cannabis products containing THC.’

Cronos Group (NASDAQ: CRON) (TSX: CRON)

The Canadian firm, though primarily an equity investor, has made some major moves in recent years, wheeling and dealing with some of the hottest names in the sector. Because of its forward-thinking attitude, it has drawn the attention of many major mainstream players, including the company behind Marlboro, Altria Group.

On December 7th, rumors were finally confirmed when Cronos made the official announcement of a C$2.4 billion strategic investment from Altria. ‘Altria is the ideal partner for Cronos Group, providing the resources and expertise we need to meaningfully accelerate our strategic growth,’ said Cronos Group”s Mike Gorenstein, Chairman, President and Chief Executive Officer.

Canopy Growth Corporation (NYSE:CGC) (TSX:WEED)

Canopy has not stopped making moves in the market, most recently swallowing up renowned vaporizer producer Stor & Bickel Gmbh & Co., the creator of the iconic Volcano® Medic and the Mighty® Medic devices

The €145 million all-cash deal makes it one of the largest in the marijuana sector this year, and Canopy Growth is not likely to stop there.

Emblem Corp. (OTCMKTS:EMMBF) (TSX.V: EMC)

Recently, Emblem completed testing on a new oral extended release product with partner Canntab Therapeutics. With the successful tests, the companies announced that they will be moving forward into clinical trials.

In addition to its advancements in the medial field, Emblem is also working towards a safer community, partnering with DriveABLE in an effort to curb accidents from impaired drivers. Nick Dean, CEO, Emblem Corp. explained, ‘Impairment – whether from alcohol, cannabis, fatigue, underlying medical conditions, or narcotics – is a serious issue that affects safety on roads and in the workplace.’

THC Biomed International (OTCMKTS:THCBF) (CSE:THC)

THC Biomed operates as a licensed producer under Canada”s Marihuana for Medical Purposes Regulations. It is also engaged in the research & development of the products and services to medical marijuana.

THC Biomed”s recently announced a new THC-based beverage, aiming to appeal to a broader range of consumers. John Miller CEO explained, ‘THC has conducted extensive research on cannabis edibles and beverages and I have found our product to be exclusive in its category.’

Though THC Biomed may be smaller than some of its more well-known competitors, it is just as ambitious. And it”s beginning to pay off. Earlier this month, the company made its first shipment of cannabis products to its Saskatchewan partner, and is rapidly expanding its holdings, with two new strata lot purchases, adding to its growing array of assets.

By. Joao Piexe

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that cannabis use and sales will grow as currently predicted; Wayland”s intended acquisition of various foreign companies and expansion into international markets; Wayland”s plans to bring automation and the latest technology to projects in various locations throughout the world; that it could be granted growing licenses; that Wayland can close on its announced purchases and joint ventures; that through efficiency and technology Wayland can substantially lower its production costs below competitors; that Wayland can sell its product at huge gross margins; that Wayland will create a range of cannabis consumer brands, to be distributed through their own digital platforms and retail facilities; that Wayland can successfully integrate pharmaceutical breakthroughs into its products; that Wayland can achieve its sales targets and gross profit margins as planned; and that it will be able to carry out its business plans.

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Wayland. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; announced or expected acquisitions or joint ventures may not close because of inability to come to final terms, or inability to obtain regulatory compliance; potential future competition in the markets Wayland operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; interruption or failure of information or other technology systems; the cannabis market may not grow as expected; Wayland”s technology and drive for efficiency may not achieve the expected results and its accomplishments may be limited; Wayland may not successfully develop a cannabis consumer brand; and it may not be successful in developing a cannabis based treatment for medical uses; even if it develops a successful treatment, it may not be able to protect its intellectual property; its patent applications may be rejected or successfully challenged; Wayland”s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal laws; and regulatory risks relating to Wayland”s business, financings and strategic acquisitions.

DISCLAIMERS

PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Safehaven.com, Leacap Ltd, and their owners, managers, employees, and assigns (collectively ‘the Company’) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Wayland fifty-eight thousand three hundred thirty three US dollars for this article and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Wayland to conduct investor awareness advertising and marketing for Wayland. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.

SHARE OWNERSHIP. The owner of Safehaven.com will not notify the market when it decides to buy or sell shares of this issuer in the market. The owner of Safehaven.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don”t trade with money you can”t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

DISCLAIMER: Safehaven.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with Safehaven.com or any company mentioned herein. The commentary, views and opinions expressed in this release by Safehaven.com are solely those of Safehaven.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ‘Forward-looking statements’ describe future expectations, plans, results, or strategies and are generally preceded by words such as ‘may’, ‘future’, ‘plan’ or ‘planned’, ‘will’ or ‘should’, ‘expected,’ ‘anticipates’, ‘draft’, ‘eventually’ or ‘projected’. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company”s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact – FN Media Group LLC
e-mail:  editor@financialnewsmedia.com  
U.S. Phone: +1(954)345-0611

LONDON, December 21, 2018 /PRNewswire/ —

Read Full Article

According to the new market research report Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, Services), Technology (Machine Learning, NLP, Context-Aware Computing, Computer Vision), End-Use Application, End User, and Geography Global Forecast to 2025, published by MarketsandMarkets™, the Artificial Intelligence In Healthcare Market is estimated to be valued at USD 2.1 billion in 2018 and is expected to reach USD 36.1 billion by 2025, at a CAGR of 50.2% from 2018 to 2025. The market has huge potential across various end users such as hospitals and providers, healthcare payers, and pharmaceutical and biotechnology companies. Increasingly large and complex data set available in the form of big data and growing need to reduce the increasing healthcare cost drive the growth of this market. Improving computing power and declining cost of hardware are other key factors driving the AI in healthcare market.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54679303

AI in healthcare market for software to hold largest market during forecast period 

The AI in healthcare market for software segment is expected to hold the largest market from 2018 to 2023. Growing adoption of AI solutions and platforms among healthcare providers and healthcare payers is the prime factor driving the growth of the software segment. The software is developed using AI technologies, such as machine learning, natural language processing, and deep learning. In most cases, the software can run in the existing system without any additional requirement for specific hardware.

Machine learning technology to witness highest CAGR from 2018 to 2025 

Machine learning technology is expected to hold the largest market share throughout the forecast period. Increasing adoption of machine learning technology (especially deep learning) in various healthcare applications is driving the growth of machine learning technology in AI in healthcare market. The major types of machine learning technology are deep learning, supervised learning, unsupervised learning, and reinforcement learning.

Browse in-depth TOC on Artificial Intelligence in Healthcare Market

65 Tables  

49 Figures  

216 Pages  

North America leads AI in healthcare market in terms of value 

North America to account for the largest size of the AI in healthcare market throughout the forecast period. The wide-scale adoption of AI technologies across the continuum of care, especially in the US, is the key factor supporting the growth of the AI in healthcare market in this region. In addition, the strong presence of key AI hardware and software providers, such as NVIDIA (US), Intel (US), Xilinx (US), Microsoft (US), AWS (US), Google (US), IBM (US), Johnson and Johnson (US), and GE (US), is complementing the growth of the AI in healthcare market in the region.

Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=54679303    

The major companies profiled in this report are NVIDIA (US), Intel (US), IBM (US), Google (US), Microsoft (US), AWS (US), General Vision (US), GE Healthcare (US), Siemens Healthineers (Germany), Medtronic plc (US). The market has active participation of start-ups. A few emerging companies in the market are CloudMedx (US), Imagia Cybernetics (Canada), Precision Health AI (US), and Cloud  Pharmaceuticals (US).

Please Explore Relevant Report Artificial Intelligence Market also.

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/artificial-intelligence-healthcare-market.asp

Visit Our Web Site: https://www.marketsandmarkets.com

CHICAGO, December 17, 2018 /PRNewswire/ —

Read Full Article